378 related articles for article (PubMed ID: 38791160)
21. Novel rhythms of N1-acetyl-N2-formyl-5-methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation.
Tan DX; Manchester LC; Di Mascio P; Martinez GR; Prado FM; Reiter RJ
FASEB J; 2007 Jun; 21(8):1724-9. PubMed ID: 17314136
[TBL] [Abstract][Full Text] [Related]
22. Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders.
Onaolapo OJ; Onaolapo AY; Olowe OA; Udoh MO; Udoh DO; Nathaniel TI
Curr Neuropharmacol; 2020; 18(7):563-577. PubMed ID: 31885352
[TBL] [Abstract][Full Text] [Related]
23. Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs.
Alamdari AF; Rahnemayan S; Rajabi H; Vahed N; Kashani HRK; Rezabakhsh A; Sanaie S
Pharmacol Res; 2021 Nov; 173():105839. PubMed ID: 34418564
[TBL] [Abstract][Full Text] [Related]
24. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites.
Reiter RJ; Tan DX; Jou MJ; Korkmaz A; Manchester LC; Paredes SD
Neuro Endocrinol Lett; 2008 Aug; 29(4):391-8. PubMed ID: 18766165
[TBL] [Abstract][Full Text] [Related]
25. [Effects of melatonin in the brain of the senescence-accelerated mice-prone 8 (SAMP8) model].
Gutierrez-Cuesta J; Tajes M; Jimenez A; Camins A; Pallas M
Rev Neurol; 2011 May; 52(10):618-22. PubMed ID: 21488009
[TBL] [Abstract][Full Text] [Related]
26. Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release.
Silva SO; Rodrigues MR; Ximenes VF; Bueno-da-Silva AE; Amarante-Mendes GP; Campa A
J Neuroimmunol; 2004 Nov; 156(1-2):146-52. PubMed ID: 15465605
[TBL] [Abstract][Full Text] [Related]
27. Optimized synthesis of the melatonin metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK).
Ximenes VF
J Pineal Res; 2008 Oct; 45(3):297-301. PubMed ID: 18373552
[TBL] [Abstract][Full Text] [Related]
28. Melatonin and its metabolite N(1)-acetyl-N(1)-formyl-5-methoxykynuramine improve learning and memory impairment related to Alzheimer's disease in rats.
Rong K; Zheng H; Yang R; Liu X; Li L; Chen N; Zhao G; Gong C; Deng Y
J Biochem Mol Toxicol; 2020 Feb; 34(2):e22430. PubMed ID: 31833155
[TBL] [Abstract][Full Text] [Related]
29. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines.
Hardeland R; Tan DX; Reiter RJ
J Pineal Res; 2009 Sep; 47(2):109-126. PubMed ID: 19573038
[TBL] [Abstract][Full Text] [Related]
30. Melatonin hormone as a therapeutic weapon against neurodegenerative diseases.
Asefy Z; Khusro A; Mammadova S; Hoseinnejhad S; Eftekhari A; Alghamdi S; Dablool AS; Almehmadi M; Kazemi E; Sahibzada MUK
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):99-106. PubMed ID: 34933727
[TBL] [Abstract][Full Text] [Related]
31. Novel pathway for N1-acetyl-5-methoxykynuramine: UVB-induced liberation of carbon monoxide from precursor N1-acetyl-N2-formyl-5-methoxykynuramine.
Seever K; Hardeland R
J Pineal Res; 2008 May; 44(4):450-5. PubMed ID: 18194200
[TBL] [Abstract][Full Text] [Related]
32. Melatonin enhances photo-oxidation of 2',7'-dichlorodihydrofluorescein by an antioxidant reaction that renders N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK).
Hevia D; Mayo JC; Tan DX; Rodriguez-Garcia A; Sainz RM
PLoS One; 2014; 9(10):e109257. PubMed ID: 25275380
[TBL] [Abstract][Full Text] [Related]
33. Melatonin and brain inflammaging.
Hardeland R; Cardinali DP; Brown GM; Pandi-Perumal SR
Prog Neurobiol; 2015 Apr; 127-128():46-63. PubMed ID: 25697044
[TBL] [Abstract][Full Text] [Related]
34. Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
Leja-Szpak A; Nawrot-Porąbka K; Góralska M; Jastrzębska M; Link-Lenczowski P; Bonior J; Pierzchalski P; Jaworek J
Pharmacol Rep; 2018 Dec; 70(6):1079-1088. PubMed ID: 30308458
[TBL] [Abstract][Full Text] [Related]
35. The antiapoptotic activity of melatonin in neurodegenerative diseases.
Wang X
CNS Neurosci Ther; 2009; 15(4):345-57. PubMed ID: 19818070
[TBL] [Abstract][Full Text] [Related]
36. Antioxidants and neuroprotection in the adult and developing central nervous system.
Kaur C; Ling EA
Curr Med Chem; 2008; 15(29):3068-80. PubMed ID: 19075654
[TBL] [Abstract][Full Text] [Related]
37. Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders.
Ganie SA; Dar TA; Bhat AH; Dar KB; Anees S; Zargar MA; Masood A
Rejuvenation Res; 2016 Feb; 19(1):21-40. PubMed ID: 26087000
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial medicine for aging and neurodegenerative diseases.
Reddy PH
Neuromolecular Med; 2008; 10(4):291-315. PubMed ID: 18566920
[TBL] [Abstract][Full Text] [Related]
39. Melatonin and its kynurenin-like oxidation products affect the microbicidal activity of neutrophils.
Silva SO; Carvalho SR; Ximenes VF; Okada SS; Campa A
Microbes Infect; 2006 Feb; 8(2):420-5. PubMed ID: 16242372
[TBL] [Abstract][Full Text] [Related]
40. Retardation of brain aging by chronic treatment with melatonin.
Bondy SC; Lahiri DK; Perreau VM; Sharman KZ; Campbell A; Zhou J; Sharman EH
Ann N Y Acad Sci; 2004 Dec; 1035():197-215. PubMed ID: 15681809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
